Fellowship in Diabetes Mellitus is a programme of one year has been developed to address the gap in medical education & contact program and simulation training.
How To Prevent Diabetes Type 2? You have just discovered that you are prediabetic. You can take meaningful steps to reduce your risk of diabetes. You can actually prevent diabetes simply by changing what you eat and how you invest in your physical health. The ball, my friend, is still in your court.
Around 8.3 percent population in the US has diabetes. Type II is the most prevalent form of diabetes. It is common among the young and the obese. Diabetes Mellitus or simply diabetes is a group of metabolic disorders characterized by an increase in your blood sugar. This results from an inadequate amount of insulin in the body or the cells' inability to respond to insulin.
Diabetes mellitus is a disease that causes the body's blood sugar levels to rise. This usually occurs when your body is unable to utilise insulin. For more any health related services you can call on this phone number - 88569-88569 and visits our website - https://www.medpho.com/
Department of Health and Social Care (DHSC) has issued a medicine supply notification for GLP-1 receptor agonists used in the management of type 2 diabetes
on Tuesday (27 June).
"There are very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs) licensed in the management of Type 2 Diabetes
Mellitus (T2DM)," said DHSC.
The supply issues have been caused by an increase in demand for these products for licensed and off-label indications and it is not expected to return to
normal until at least mid-2024.
Pharmacists are urged to refer to the SPS Tool for Medicines Shortages for an up-to-date supply stock situation and clinical guidance on alternative
treatment options.
The Medicines and Health products Regulatory Agency (MHRA) on Thursday issued a class 4 medicines defect information notice for Cozaar 100mg film-coated
tablets due to an error in the Patient Information Leaflets (PILs) reported by the company.
Cozaar is used to treat high blood pressure (hypertension) as well as to slow the progression of kidney disease in people who have type 2 diabetes mellitus.
Quadrant Pharmaceuticals Ltd has informed the UK regulatory authority that the PILs that have been packed in certain batches of the products do not have the most
up to date safety information.
'Grapefruit juice should be avoided while taking Cozaar'- This information is missing in Section 2 'What you need to know before you take Cozaar', sub section
'Cozaar with food and drink', the company clarified.
Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug.
Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing
type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes.
Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION).
To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at
Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.
The number of people in England identified as at risk for type 2 diabetes mellitus (T2DM) has increased by over half a million within a year, according to
NHS figures.
Data released by the National Diabetes Audit on June 12 showed that 3.6 million people registered with a GP were found to have non-diabetic hyperglycaemia
(also known as pre-diabetes) in 2023, compared with 3.1 million people in 2022 - a notable 18 per cent increase or nearly 550,000 people.
Among those under 40 years old, the figures showed an increase of almost 25 per cent from 173,166 in 2022 to 216,440 in 2023.
People with non-diabetic hyperglycaemia have higher-than-normal blood sugar levels, and they are at greater risk for developing type 2 diabetes and
cardiovascular diseases. Typically, this condition is detected through routine blood tests at GP surgeries.
PBR Staff Writer Published 27 March 2014 The European Commission (EC) has granted marketing authorization for GlaxoSmithKline's (GSK's) once-weekly diabetes treatment, Eperzan (albiglutide). The drug is indicated for the treatment of type 2 diabetes mellitus in adults, to improve glucose control as monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to contraindications or intolerance.